Name: Tazarotene
Brand: Selleck Chemicals
SKU: S1569
Availability: InStock
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Retinoid Receptor Inhibitors	TTNPB (Arotinoid acid) Tamibarotene AM580 Fenretinide BMS493 SR 11237 UVI 3003 AR7 Palovarotene CD1530

Solubility

In vitro
Batch:

DMSO : 10 mg/mL (28.45 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (3.56mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (3.56mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	351.46	Formula	C₂₁H₂₁NO₂S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	118292-40-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AGN190168			SMILES	CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	RAR
In vitro	Tazarotene causes ERK activation, RB tumor suppressor protein hypophosphorylation, G0 arrest, and myeloid differentiation in HL-60 human myeloblastic leukemia cells. This compound could propel either early or late portions of the period leading to differentiation and G0 arrest and is interchangeable with an RARalpha-selective ligand. It regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis. This chemical inhibits the proliferation of fibroblasts and synthesis of DNA and collagen. It down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. This agent also up-regulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect. It causes growth suppression in retinoid-responsive breast cancer cell lines by up-regulating TIG3.
In vivo	Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in UV-treated Ptch1+/− mice. This compound also reduces the number and size of microscopic basal cell carcinomas (BCCs) in ionizing radiation-treated Ptch1+/− mice.
References	[1] https://pubmed.ncbi.nlm.nih.gov/15383624/ [2] https://pubmed.ncbi.nlm.nih.gov/15989518/ [3] https://pubmed.ncbi.nlm.nih.gov/9593227/ [4] https://pubmed.ncbi.nlm.nih.gov/9270552/ [5] https://pubmed.ncbi.nlm.nih.gov/15231643/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-10-30)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06331624	COMPLETED	Idiopathic Pulmonary Fibrosis; IPF	GRI Bio Operations, Inc.	2024-04-24	PHASE2
NCT06042647	COMPLETED	Psoriasis Vulgaris	Dermatology Consulting Services, PLLC	2023-07-13	PHASE4
NCT05872256	COMPLETED	Scalp Psoriasis	Dermatology Consulting Services, PLLC	2023-06-01	PHASE4
NCT05555797	UNKNOWN	Psoriasis	Assiut University	2022-10-30	PHASE4
NCT06015152	COMPLETED	Scalp Psoriasis	Jinnah Postgraduate Medical Centre	2022-08-01
NCT05314127	UNKNOWN	Warts Flat	Zagazig University	2022-04-15	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Tazarotene Retinoid Receptor agonist

Chemical Structure

Molecular Weight: 351.46